LUNG CANCER

Dr Christine Bestvina discusses EGFR treatment shifts, KRAS trial data, and expanding clinical trial access for community oncologists.

Nuvalent has submitted an NDA to the FDA for neladalkib, a brain-penetrant ALK-selective TKI for pretreated advanced ALK-positive NSCLC.

The ASTEROID trial shows adding durvalumab to SBRT significantly cuts tumor progression in early-stage NSCLC, though OS and DFS benefits remain uncertain.

Experts review a stage IV NSCLC case, debating whether to delay treatment while awaiting PD-L1 results to ensure a more precise, tailored therapy plan.

FDA fast tracks TRI-611, an ALK molecular glue degrader for refractory ALK+ NSCLC. Phase 1/2 trial targets resistance after 2 or more TKIs.

The proposed biosimilar demonstrated clinical equivalence to the reference product in overall response rate at 18 weeks, with a comparable safety profile, supporting regulatory submissions.

Phase 1 data show that setidegrasib degrades KRAS G12D, delivering durable NSCLC responses with manageable safety and biomarker-linked benefit as phase 3 plans advance.

Phase 3 data show oral sunvozertinib beats platinum chemo in EGFR exon 20ins NSCLC, boosting PFS and responses with tolerable safety.

ELCC 2026 spotlights lung cancer breakthroughs—ADCs, EGFR combo sequencing, HER2 TKIs and SCLC bispecifics—reshaping treatment choices.

Aglatimagene besadenovec intratumoral gene therapy plus valacyclovir shows durable survival in ICI-resistant advanced NSCLC, fueling pivotal phase 3 plans.

Phase 3 NSCLC study of eftilagimod alfa with pembrolizumab and chemo stops early after futility review, raising questions about LAG-3 strategy.

IASLC TTLC 2026 spotlights patient voices, ctDNA MRD, EGFR co-mutations, and ADCs—plus real-world gaps in testing and multidisciplinary lung care.

An interview with Joshua Reuss, MD, thoracic medical oncologist at Georgetown University and co-author of the guidelines.

TTLC 2026 spotlights next-gen lung cancer therapies, co-mutation strategies, and ctDNA monitoring—insights beyond CME for what’s coming next.

FDA clears zongertinib for HER2-mutant advanced nonsquamous NSCLC, showing strong responses and promising brain metastasis activity.

Explore frontline chemo‑immunotherapy choices in extensive-stage SCLC, NCCN updates, and why patient drop-off shapes second- and third-line care.

WVU Medicine pioneers nonthermal PEF therapy for metastatic lung nodules, using robotic bronchoscopy to target tumors precisely and potentially boost immune response.

Discover how precision lung cancer care tackles gene fusions, new HER2/ROS1/ALK drugs, expanded screening, and liquid biopsies shaping 2026 treatment.

FDA approves monthly subcutaneous amivantamab plus lazertinib for EGFR-mutated advanced NSCLC, cutting clinic time and infusion reactions while maintaining efficacy.

Adjuvant selpercatinib boosts event-free survival after surgery in early-stage RET fusion–positive NSCLC, signaling a potential new standard and expanding genomic testing.

FDA RMAT boosts inhaled gene therapy KB707, delivering IL‑2/IL‑12 to lung tumors; early trial shows responses with manageable safety.

New targeted drugs transform HER2, ROS1 and ALK lung cancer care, boosting brain response and survival—while precision choices still matter.

South Florida’s diverse lung cancer cases fuel genomic breakthroughs, push screening beyond smokers, and accelerate 2026 targeted-therapy progress.

A recent study reveals significant progress in biomarker testing for lung cancer in community settings, highlighting the need for improved access to targeted therapies.